Articles tagged with Chimeric Antigen Receptors
Researchers have made a significant breakthrough in immunotherapy design, using specifically designed receptors to completely clear brain cancer tumors in preclinical models. The approach has shown promise and could pave the way for new treatments for people with glioblastoma, an aggressive form of brain cancer.
Researchers have developed a new generation of CAR T cells that safely target and kill solid tumors in mice with mesothelioma, ovarian cancer, and glioblastoma. The 'prime-and-kill' molecular circuits enable specific recognition of tumor antigens on healthy tissues, reducing the risk of side effects.
Researchers found that a shorter 'linker' on CAR T cells improves their response to B-cell acute lymphoblastic leukemia. The study suggests that modifying the length of linkers can improve CAR T cell function and overcome current limitations.
Researchers have developed a new chimeric antigen receptor (CAR) T cell immunotherapy that targets both CD19 and CD20 proteins, achieving complete metabolic responses in four out of five patients with relapsed or refractory B-cell lymphoma. The approach minimizes treatment resistance and prevents relapse by recognizing multiple targets.
Researchers found that T cells in the small intestine have evolved a molecular sensing mechanism to protect themselves from toxic bile acids. This mechanism can be manipulated with small drug-like molecules, reducing inflammation and improving symptoms.
The study shows that using a truncated form of the CD4 molecule as part of a gene therapy yields superior and longer-lasting results in mouse models than previous similar therapies. The new approach to CAR T gene therapy has the potential to create lifelong protection from HIV infection by producing memory cells.
A new study finds that stem cell transplants after CAR T-cell therapy reduce relapse rates in childhood cancer patients by less than 10% two years later. The research suggests long-term benefits for young patients who receive the treatment, with most experiencing complete remission.
Researchers integrated clinical data with mathematical and statistical modeling to study the competition between normal T cells and CAR T cells. The model confirmed that tumor eradication is a random, yet potentially highly probable event, with cures happening early after treatment.
Researchers have developed a new CAR T cell engineering technique that allows for the targeting of solid tumors without harming healthy cells. The technique uses ultrasensitive identification of HER2 protein on tumor cells and has shown promise in treating ovarian cancer.
A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times. Nearly three-quarters of the patients had at least a partial response to the therapy, with about a third achieving complete remission.
Researchers successfully targeted Cryptococcus species using reprogrammed CAR T-cells, effectively controlling the growth of fungi. The treatment showed promising results in vitro and in mice, with reduced titan cells indicating a good prognosis for new treatments. This innovative approach could also be applied to other fungal infections.
A significant number of NHL patients achieved complete remission and progression-free survival with Kymriah, a personalized cellular therapy. The study demonstrated the durability of this approach, with most patients remaining in remission five years after treatment.
A multidisciplinary team from Memorial Sloan Kettering reports the presence of inflammatory molecules in the cerebrospinal fluid as the underlying cause of 'COVID brain' or brain fog, a condition characterized by confusion and loss of short-term memory. Anti-inflammatory drugs like steroids may be useful for treating the condition.
Research at H. Lee Moffitt Cancer Center & Research Institute identified immune dysregulation as a key factor hindering CAR T-cell expansion and effectiveness in diffuse large B-cell lymphoma patients. The study suggests that addressing underlying immune characteristics may improve treatment outcomes.
A protein called CEACAM7 has been identified as a potential therapeutic target for pancreatic cancer, offering a safer alternative to current treatments. This discovery has led to the successful development of CAR T cell therapy, which effectively targeted and killed pancreatic cancer cells in a pre-clinical model.
Researchers at Children's Hospital Los Angeles have developed a new CAR T therapy that targets solid tumors in children, including neuroblastoma. The modified therapy uses a unique protein called synNotch to selectively kill cancer cells while sparing healthy tissue.
Researchers developed a CD45-directed antibody radioconjugate to target and deplete specific immune cells. The treatment safely depleted T cells, B cells, NK cells, and Tregs in mice while sparing red blood cells and platelets.
Researchers developed molecular ON-OFF switches to regulate CAR T cell activity, potentially reducing toxic side effects. The switches use an FDA-approved drug to turn off or on the cells' anti-tumor function.
A new study suggests that adding a small molecule to CAR-T cell therapy can boost the effectiveness of immunotherapy against breast cancer and other solid tumors. Researchers found that the addition of cGAMP activated an immune response, leading to enhanced T cell proliferation and tumor growth reduction.
Researchers found that combining CAR T cells with a proinflammatory environment created by STING pathway activation can improve their ability to attack tumor cells. This approach, combined with therapeutic antibodies, led to the complete eradication of breast tumors in mice.
Baylor College of Medicine researchers found that long-term exposure to IFNγ exhausts blood stem cells by triggering proliferation and excessive differentiation. Modulating BST2 expression on these cells may provide a means to regulate their activation during chronic infections.
Researchers found that keeping STAT5 active in CAR T cells improves their persistence and tumor-killing ability. This breakthrough could lead to more effective cancer treatments, but further research is needed.
Researchers have found that knocking out the CD5 gene on CAR T cells using CRISPR-Cas9 technology enhances their ability to eliminate blood cancers. Mice infused with CD5-deleted CAR T cells showed higher T cell proliferation and reduced tumor size compared to non-edited cells.
Axicabtagene ciloleucel (axi-cel) achieved undetectable cancer levels in nearly 80% of patients, and durable responses in most participants. The therapy demonstrated improved response rates for follicular lymphoma compared to marginal zone lymphoma.
A novel T cell genetically engineered by University of Arizona Health Sciences researchers targets and attacks pathogenic T cells that cause Type 1 diabetes. The 5MCAR T cells, which mimic the evolutionary design of natural killer T cells, were tested in a non-obese diabetic mouse model with promising results.
Combining CAR T cell therapy with a PAK4 inhibitor improved T cell infiltration and reduced solid tumors in mice. The study found that inhibiting the enzyme PAK4 helped normalize the tumor microenvironment, allowing T cells to attack the tumor more effectively.
A novel CAR T-cell therapy has shown promising early results in children with relapsed or refractory neuroblastoma. The treatment induced rapid reduction in tumor size, but effects were transient. Researchers are optimistic about the potential of this immunotherapy as a future treatment for solid cancers in children.
A phase 1 trial involving 12 children with relapsed neuroblastoma found CAR T cells effective against tumors without damaging nerve tissue. The treatment showed signs of antitumor immunity in some patients and may be further modified to boost persistence within tumors.
A new Penn study found administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was safe and did not interfere with cellular therapy. Patients who received radiation 34 days or fewer before infusion had similar rates of severe side effects as those who did not receive radiation.
Researchers developed CAR NKT cells to target neuroblastoma, a childhood cancer. The modified cells showed safety, localization to tumors, and induced an objective response with regression of bone metastatic lesions in one patient.
A study at MD Anderson Cancer Center found that monitoring early changes in circulating tumor DNA can predict patient outcomes. Infused CAR T cells with certain characteristics are associated with better treatment responses, while those with exhaustion signatures may experience poor outcomes.
Researchers have developed a new Dual CAR T cell immunotherapy that targets the HIV reservoir and combats HIV infection in humanized mice. The therapy, which combines two CARs into a single T cell, provides a strong and long-lasting response against HIV-infection while being resistant to the virus itself.
A study led by Avery Posey reveals the presence of CD19, a B cell molecule targeted by CAR T cell immunotherapy, in brain cells that protect the blood-brain barrier. This finding may be linked to neurotoxicity in patients undergoing CD19-directed CAR T cell therapy.
Researchers successfully combined two immunotherapies to target and eliminate difficult-to-treat solid tumors. The combination showed a powerful, synergistic effect, leading to prolonged protective anti-tumor immunity in mice.
Researchers develop Dual CAR T cell immunotherapy to target HIV reservoir, showing promise in controlling viral replication and preserving CD4+ T cells. The therapy was effective in slowing HIV replication, killing infected cells, and suppressing the virus with ART.
Researchers found that CAR T cells targeting the HER2 protein on cancer cells led to a sustained tumor response. The child's immune system was recruited to act against the tumor, suggesting a potential novel approach to fighting difficult-to-treat cancers.
Researchers found that high levels of pre-treatment interleukin 6 indicate a high risk for neurotoxicity and cytokine release syndrome from CAR T therapy. The study also suggests that targeting the tumor microenvironment prior to therapy may help reduce inflammation and toxicities.
Researchers developed engineered natural killer immune cells expressing a PD-L1 CAR that directly kill tumour cells in mice and humans. The treatment also reduces the numbers of immunosuppressive myeloid cells harbouring PD-L1.
Researchers at the German Cancer Research Center found that CAR T cell production can be significantly reduced in an academic setting, from EUR 320,000 to around EUR 60,000. This could lead to substantial cost savings and faster treatment times for patients, as well as increased accessibility of this life-saving therapy.
Researchers at Memorial Sloan Kettering have engineered CAR T cells to recognize and eliminate senescent cells, which contribute to various debilitating diseases. The uPAR-directed approach has shown promise in mouse models of liver fibrosis and lung cancer, offering hope for new treatments.
A Moffitt Cancer Center study found that CAR T-cell therapy, Yescarta, is effective in patients with relapsed/refractory large B cell lymphoma who would not have qualified for clinical trials. The study showed an overall response rate of 82% and durable response rate of 47%, suggesting that these patients can benefit from the therapy.
Research highlights continued support for immunotherapy approaches to pediatric ALL and lung cancer, as well as progress in Cancer Interception. The studies aim to identify genes that may be responsible for immune suppression or activation in Bronchial premalignant lesions.
Researchers develop novel approach to deliver CAR T cell therapy directly into cerebrospinal fluid, effectively treating medulloblastoma and ependymoma in mouse models. Combining immunotherapy with azacytidine significantly enhances treatment efficacy.
Researchers from Duke-NUS Medical School are exploring a new therapy using patient's own immune cells to target infectious diseases, including COVID-19. The therapy involves engineering virus-targeting receptors onto T lymphocytes, allowing them to recognize and kill infected cells.
Scientists have successfully engineered CAR macrophages to target and kill solid tumors, using a novel approach that could lead to more effective cancer treatments. The discovery centers around harnessing the immune-boosting properties of macrophages, which are often co-opted by tumors.
Researchers developed a new CAR T cell therapy using chlorotoxin, a component of scorpion venom, to target glioblastoma cells. The therapy showed promise in killing tumor cells while ignoring healthy tissue.
Researchers at UC San Diego developed a system to control CAR T cells using blue light, destroying skin tumors without harming healthy tissue. In tests, the treatment reduced tumor size by 8-9 fold in 90% of mice.
Researchers have engineered immune cells to target solid tumors using a new cancer immunotherapies approach. They found that T cells can be reprogrammed to turn on tumor cells when exposed to high concentrations of transforming growth factor beta, a protein that suppresses the activity of T cells in the tumor environment.
Researchers at Huntsman Cancer Institute developed a novel CAR T cell therapy targeting CD229, a molecule present on cancer cells and stem cells in patients with multiple myeloma. Laboratory tests showed promising results, including the ability to kill mature multiple myeloma cells and myeloma stem cells.
The CD19 CAR NK-cell therapy achieved a 73% response rate in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities reported. The treatment was administered in an outpatient setting, and responses were evident within one month following infusion.
A new protein-based method, STOP-CAR, switches off modified T cells on command, reducing toxicity and organ damage in cancer patients. This breakthrough could speed the clinical development of new CAR therapies.
Researchers discovered a death receptor pathway in cancer cells that prevents them from dying, leading to T cell dysfunction and resistance to CAR T cell therapy. The study's findings may provide guidance for future immunotherapies in patients resistant to CAR T therapy.
Researchers have discovered ways to boost CAR T-cell therapy, surveying over 500 cancer drugs on its function. SMAC mimetics sensitize cancer cells to CAR T cells, while inhibiting CAR T cell functions could treat adverse effects.
A one-year follow-up study of CAR T-cell therapy for relapsed mantle cell lymphoma found that 93% of patients responded to the treatment, with 67% achieving a complete response. The therapy was shown to be effective and viable option for patients with relapsed or refractory mantle cell lymphoma.
A global trial found mosunetuzumab, an off-the-shelf antibody, can induce complete responses in patients with relapsed or refractory non-Hodgkin lymphoma. Higher doses of the drug correlate with patient responses, and remissions appear to be long-lasting.
A new tool called Long-term Investor Value Appropriation (LIVA) has been introduced to measure long-term firm performance and shareholder value. LIVA uses stock price data to calculate a backward-looking net present value over a given period, providing a more accurate reflection of underlying economic performance.
Researchers genetically engineered CAR T cells with molecular tags, allowing them to be monitored in animal models using PET imaging. This technology enables clinicians to track the number and location of CAR T cells over time, providing a more accurate measure of therapy durability and potential efficacy.
Researchers from Xyphos and Gladstone Institutes published preclinical data demonstrating that convertibleCAR cells can significantly reduce latent reservoirs of diverse HIV strains. This approach targets specific cells for destruction using bispecific MicAbodies, providing a promising solution to the HIV/AIDS cure.
Researchers at UCLA Jonsson Comprehensive Cancer Center are launching a pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial targeting CD19 and CD20 proteins on B-cell lymphoma and leukemia. The goal is to minimize resistance and increase life expectancy for patients diagnosed with these cancers.
Researchers developed a system that allows for spatiotemporal control of CAR T-cell therapy, enabling cancer cells to target specific locations and times. This approach reduces the risk of non-specific targeting of organs and normal tissues, potentially improving treatment outcomes.